The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1/2, first-in-human, open-label, dose-escalation study of TAK-280, an investigational B7-H3 x CD3ε conditional bispecific redirected activation (COBRA) T-cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors.
 
Gary Edward Richardson
Research Funding - Adagene (Inst); Agenus (Inst); AstraZeneca (Inst); BeiGene (Inst); Bio-Thera Solutions (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CBT Pharmaceuticals (Inst); ChemoCentryx (Inst); Corvus Pharmaceuticals (Inst); Curon Biopharmaceutical (Inst); D3 Bio (Inst); Eucure Biopharma (Inst); Five Prime Therapeutics (Inst); Fosun Pharma (Inst); Gene Quantum (Inst); Genfleet Therapeutics (Inst); ImmunGen Inc (Inst); Imugene (Inst); InventisBio (Inst); Janssen Oncology (Inst); Keythera Pharmaceuticals (Inst); LaNova Australia (Inst); Medicenna (Inst); Merck (Inst); Minghui Pharmaceutical (Inst); Neoleukin Therapeutics (Inst); Novotech (Inst); Pfizer (Inst); PharmAbcine (Inst); RemeGen (Inst); Roche/Genentech (Inst); Seagen (Inst); Senz Oncology (Inst); Shanghai Henlius Biotech (Inst); Shanghai Henlius Biotech (Inst); Surface Oncology (Inst); Suzhou Alphamab (Inst); Takeda (Inst); Therapim (Inst); Zentalis (Inst)
 
Ganessan Kichenadasse
No Relationships to Disclose
 
Nicholas Zorko
Travel, Accommodations, Expenses - Caris Life Sciences; Telix Pharmaceuticals
 
Wen Wee Ma
Consulting or Advisory Role - Kodikaz Therapeutic Solutions
Research Funding - Actuate Therapeutics (Inst); Athenex (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Cardiff Oncology (Inst); CUE Biopharma (Inst); Elucida Oncology (Inst); Genentech (Inst); Ipsen (Inst); Jacobio (Inst); Merus (Inst); Repare Therapeutics (Inst); Sun Pharma (Inst)
 
Huizi Chen
Speakers' Bureau - Jazz Pharmaceuticals
 
David Starks
No Relationships to Disclose
 
Sarah Sutherland
No Relationships to Disclose
 
Sujana Kamasani
Employment - Takeda
Stock and Other Ownership Interests - Takeda
 
Antari Khot
Employment - Takeda
Stock and Other Ownership Interests - Takeda
 
Xin Ma
Employment - Takeda
 
William L. Trepicchio
Employment - Takeda
Leadership - Senior Director
Stock and Other Ownership Interests - Takeda
 
Yefei Zhang
Employment - Takeda
Stock and Other Ownership Interests - Takeda
 
Elizabeth Stephanie Ahern
Honoraria - MSD Oncology
Research Funding - Amgen (Inst)
Patents, Royalties, Other Intellectual Property - U.S. Provisional Application No. 62/775803
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb